Who are chondrocyte-alginate gel suspension's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, Allogenix Plus, Cytokine-induced killer cells+ FOLFOX4, ASC, SkinTE, Cord Blood Cell.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chondrocyte-alginate-gel-suspension.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

chondrocyte-alginate gel suspension — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

chondrocyte-alginate gel suspension (chondrocyte-alginate gel suspension) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Orthopedics.

phase 3 Cell therapy Orthopedics Small molecule Live · refreshed every 30 min

Target snapshot

chondrocyte-alginate gel suspension (chondrocyte-alginate gel suspension) — FDA Office of Orphan Products Development. Chondrocyte-alginate gel suspension is a cell-based therapy that delivers chondrocytes to repair damaged cartilage.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
chondrocyte-alginate gel suspension TARGET	chondrocyte-alginate gel suspension	FDA Office of Orphan Products Development	phase 3	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Allogenix Plus	Allogenix Plus	University of Missouri-Columbia	marketed	Allogeneic cell therapy
Cytokine-induced killer cells+ FOLFOX4	Cytokine-induced killer cells+ FOLFOX4	China Meitan General Hospital	marketed	Cell therapy combined with chemotherapy
ASC	ASC	Anterogen Co., Ltd.	marketed	Autologous stem cell therapy
SkinTE	SkinTE	PolarityTE	marketed	Autologous cell therapy / Tissue-engineered product
Cord Blood Cell	Cord Blood Cell	China Spinal Cord Injury Network	marketed	Cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
Bone Therapeutics S.A · 1 drug in this class
DiscGenics, Inc. · 1 drug in this class
Celavie Bioscences, LLC · 1 drug in this class
China Spinal Cord Injury Network · 1 drug in this class
City of Hope Medical Center · 1 drug in this class
Brainstorm-Cell Therapeutics · 1 drug in this class
Dr. Grant M. Pagdin · 1 drug in this class
FDA Office of Orphan Products Development · 1 drug in this class
Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). chondrocyte-alginate gel suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/chondrocyte-alginate-gel-suspension. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab